No Data
No Data
Neumora NMRA -81% Phase 3 Failure; Curis CRIS +39% Patent
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Curis Shares Gain on Results From Leukemia-Treatment Study
Curis Files Shelf for Secondary Stock Sale
Express News | Curis Inc Files Prospectus for Resale, From Time to Time, of up to 2.4 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Express News | Curis Announces Additional Data From Takeaim Leukemia Study